Hereditary Testing Market Size, Share & Trends Analysis Report By Disease Type (Hereditary Cancer Testing, Hereditary Non-cancer Testing), By Technology, By Region (North America, Europe, APAC, LATAM, MEA)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global hereditary testing market size was exhibited at USD 6.78 billion in 2022 and is projected to hit around USD 16.49 billion by 2032, growing at a CAGR of 9.3% during the forecast period 2023 to 2032.

hereditary testing market size

Key Pointers:

  • The hereditary cancer testing disease type segment is expected to expand at a considerable rate over the forecast period. A substantial number of CLIA-certified laboratories perform tests to determine whether an individual carries an inherited mutated gene that can cause cancer
  • The breast cancer testing segment dominated the hereditary cancer testing market in 2022 owing to its high penetration and increased inheritability. Most of the cases of cervical cancer are non-hereditary, resulting in the lowest revenue share of this segment
  • In the hereditary non-cancer testing disease type segment, the cardiac diseases segment is driven by the emergence of high-throughput sequencing, which has resulted in the commercial availability of a significant number of sequencing assays for cardiomyopathies
  • The Non-invasive Prenatal Testing (NIPT) and cancer screening tests segment and the newborn genetic screening segment continue to witness lucrative growth due to the increased adoption across the globe
  • Moreover, the newborn screening program has been made mandatory in several regions and countries, resulting in the growth of newborn genetic screening in the hereditary non-cancer testing disease type segment
  • Europe and North America collectively accounted for over 66.9% share of the overall revenue in 2022 owing to the assisted reproductive technology space, coupled with the high penetration of newborn genetic screening
  • Key companies are engaged in securing regulatory approval in emerging countries to expand their business footprint. A substantial number of diagnostic companies have collaborated with technology developers to obtain technology licenses and deliver high-value services to their customers

 Hereditary Testing Market Report Scope

Report Coverage

Details

Market Size in 2023

USD 7.41 Billion

Market Size by 2032

USD 16.49 Billion

Growth Rate from 2023 to 2032

CAGR of 9.3%

Base year

2022

Forecast period

2023 to 2032

Segments covered

Disease type, Technology

Regional scope

North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa

Key companies profiled

Myriad Genetics, Inc.; Invitae Corporation; Illumina, Inc.; Natera, Inc.; Laboratory Corporation of America Holdings; F. Hoffmann-La Roche Ltd; Quest Diagnostics Incorporated; CooperSurgical, Inc.; Agilent Technologies, Inc.; Thermo Fisher Scientific, Inc.

 

The Key factors driving the market are the declining cost of sequencing and the availability of genetic tests at a lower price. Furthermore, the availability of niche and fragmented point solutions across the genomics value chain, namely sequencing, analytics, interpretation, aggregation, and marketplace, is anticipated to propel the market growth over the forecast period.

The advent of direct-to-consumer genetics is anticipated to play a major role in the genetic testing market by enabling individuals to carry out self-testing. This expands the role of genetic counselors, which further aids in understanding the importance of genetic tests and helps in the selection of appropriate tests. A growing number of registered genetic counselors is anticipated to boost the adoption of hereditary genetic tests in the coming years.

Another important market trend is the growing field of reproductive genetic health. For instance, Natera has seen a consistent increase in test numbers in hereditary illnesses genetic analysis for women's health. This indicates a rise in public acceptance of hereditary testing, which is fueling the market expansion. A rise in the trade of newborn screening equipment has corresponded with a rise in the trade of DNA experiment equipment. Progressing the sharpness of newborn screening all over the world is also assisting in earnings increase. A multigene board trial was formed for introducing genetic melanoma into the clinical application, which has been prompted by changes in genetic experimentation standards. The growing generative hereditary health scope is one of the most important key factors driving the market.

The COVID-19 pandemic had a detrimental impact on the market. For example, after the World Health Organization declared COVID-19 a pandemic, governments all around the world used lockdowns to compel social distancing as a prophylactic measure. In every industry, this resulted in upheaval, constraints, challenges, and adjustments. Similarly, the outbreak has a negative impact on the inherited genetic analysis sector.

Technology developers are introducing advanced products to enhance the efficiency of genetic tests by diagnostic companies. For example, in December 2020, the QuantiFERON SARS-CoV-2 RUO solution was introduced by QIAGEN, a business that provides technologies and products for pre-analytical samples and related molecular test solutions. The solution detects immune system T-cell responses to the infection that causes COVID-19. The solution would give precise information on illness development and immunity levels.

Some of the prominent players in the Hereditary Testing Market include:

  • Myriad Genetics, Inc.
  •  Invitae Corporation
  •  Illumina, Inc.
  •  Natera, Inc.
  •  Laboratory Corporation of America Holdings
  •  F. Hoffmann-La Roche Ltd.
  •  Quest Diagnostics Incorporated
  •  CooperSurgical, Inc.
  •  Agilent Technologies, Inc.
  •  Thermo Fisher Scientific, Inc.
  •  Twist Bioscience
  •  Sophia Genetics
  •  Fulgent Genetics, Inc.
  •  MedGenome
  •  CENTOGENE N.V.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Hereditary Testing market.

By Disease Type 

  • Hereditary Cancer Testing
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Cervical Cancer
    • Ovarian Cancer
    • Prostate Cancer
    • Stomach/Gastric Cancer
    • Melanoma
    • Sarcoma
    • Uterine Cancer
    • Pancreatic Cancer
    • Others
  • Hereditary Non-cancer Testing
    • Genetic Tests
    • Cardiac Diseases
    • Rare Diseases
    • Other Diseases
  • Newborn Genetic Screening
  • Preimplantation Genetic Diagnosis & Screening
  • Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests

By Technology 

  • Cytogenetic
  • Biochemical
  • Molecular Testing

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

The global Hereditary Testing market size was exhibited at USD 6.78 billion in 2022 and is projected to hit around USD 16.49 billion by 2032

The global hereditary testing market is expected to grow at a compound annual growth rate of 9.3% from 2023 to 2032

Key factors that are driving the hereditary testing market growth include raising awareness of women\'s reproductive health, the decline in sequencing cost, and the expansion of the genetic testing registry.

Some key players operating in the hereditary testing market include Myriad Genetics, Inc.; Invitae Corporation; Illumina, Inc.; Natera, Inc.; Laboratory Corporation of America Holdings; F. Hoffmann-La Roche Ltd; Quest Diagnostics Incorporated; CooperSurgical, Inc.; Agilent Technologies, Inc.; and Thermo Fisher Scientific, Inc.

Chapter 1 Research Methodology
                   1.1 Information Procurement
                   1.2 Information or Data Analysis
                   1.3 Market Formulation & Validation
                   1.4 Market Scope & Segment Definition
                       1.4.1 Hereditary cancer testing
                       1.4.2 Hereditary non-cancer testing
                           1.4.2.1 Genetic tests
                           1.4.2.2 Newborn genetic screening
                           1.4.2.3 Preimplantation genetic diagnosis & screening
                           1.4.2.4 Non-invasive Prenatal Testing (NIPT) & carrier screening tests
                   1.5 Market Model
                       1.5.1 Hereditary cancer testing market
                           1.5.1.1 Market study
                               1.5.1.1.1 Price case study
                               1.5.1.1.2 Test provision study
                               1.5.1.1.3 Market competition study
                               1.5.1.1.4 Reimbursement study
                           1.5.1.2 Product mapping by cancer type & company
                       1.5.2 Hereditary non-cancer genetic testing market
                           1.5.2.1 Newborn genetic screening market
                           1.5.2.2 Preimplantation genetic testing market; NIPT & carrier screening market
Chapter 2 Executive Summary
                   2.1 Market Snapshot ( 2023, USD Millions)
Chapter 3 Hereditary Testing Market Variables, Trends, & Scope
                   3.1 Market Segmentation & Scope
                   3.2 Market Dynamics
                       3.2.1 Market driver analysis
                           3.2.1.1 Increase in sales and demand for DNA test kits
                           3.2.1.2 Constantly developing commercial landscape of women's reproductive health
                           3.2.1.3 Decline in sequencing cost & consequent expansion of genetic testing registry
                       3.2.2 Market restraints analysis
                           3.2.2.1 Ethical and clinical issues of DNA tests
                           3.2.2.2 Regulatory challenges pertaining to use of DTC genetic tests
                       3.2.3 Market opportunity analysis
                           3.2.3.1 Increasing incidence of genetic diseases
                           3.2.3.2 Presence of demand for early and non-invasive fetal testing procedures
                           3.2.3.3 Introduction of fragmented point-solutions across the genomics value chain
                   3.3 Industry Pyramid Analysis
                   3.4 Technology Mapping
                       3.4.1 PGS Technology Analysis
                           3.4.1.1 aCGH
                           3.4.1.2 NGS
                           3.4.1.3 Others
                           3.4.1.4 Introduction of technological advancements in cloud computing and data integration
                   3.5 Regulatory Landscape, by Geography
                       3.5.1 U.S.
                       3.5.2 Europe
                           3.5.2.1 Germany
                       3.5.3 China
                       3.5.4 Japan
                   3.6 Penetration & Growth Prospect Mapping, Disease Type, 2023
                   3.7 Hereditary Testing Market-SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
                   3.8 Industry Analysis - Porter’s Five Forces
Chapter 4 Hereditary Testing Market: Disease Type Estimates & Trend Analysis
                   4.1 Hereditary Testing Market: Disease Type Movement Analysis
                   4.2 Hereditary Cancer Testing
                       4.2.1 Global hereditary cancer testing market, 2020 - 2032
                       4.2.2 Lung cancer
                           4.2.2.1 Global hereditary cancer testing market for lung cancer, 2020 - 2032
                       4.2.3 Breast cancer
                           4.2.3.1 Global hereditary cancer testing market for breast cancer, 2020 - 2032
                       4.2.4 Colorectal cancer
                           4.2.4.1 Global hereditary cancer testing market for colorectal cancer, 2020 - 2032
                       4.2.5 Cervical cancer
                           4.2.5.1 Global hereditary cancer testing market for cervical cancer, 2020 - 2032
                       4.2.6 Ovarian cancer
                           4.2.6.1 Global hereditary cancer testing market for ovarian cancer, 2020 - 2032
                       4.2.7 Prostate cancer
                           4.2.7.1 Global hereditary cancer testing market for prostate cancer, 2020 - 2032
                       4.2.8 Stomach/gastric cancer
                           4.2.8.1 Global hereditary cancer testing market for stomach/gastric cancer, 2020 - 2032
                       4.2.9 Melanoma
                           4.2.9.1 Global hereditary cancer testing market for melanoma, 2020 - 2032
                       4.2.10 Sarcoma
                           4.2.10.1 Global hereditary cancer testing market for sarcoma, 2020 - 2032
                       4.2.11 Uterine cancer
                           4.2.11.1 Global hereditary cancer testing market for uterine cancer, 2020 - 2032
                       4.2.1 2 Pancreatic cancer
                           4.2.1 2.1 Global hereditary cancer testing market for pancreatic cancer, 2020 - 2032
                       4.2.13 Other cancers
                           4.2.13.1 Global hereditary cancer testing market for other cancers, 2020 - 2032
                   4.3 Hereditary Non-cancer Testing
                       4.3.1 Global hereditary non-cancer testing market, 2020 - 2032
                       4.3.2 Hereditary non-cancer genetic testing
                           4.3.2.1 Global hereditary non-cancer genetic testing market, 2020 - 2032
                           4.3.2.2 Hereditary genetic testing for cardiac disease
                               4.3.2.2.1 Global hereditary genetic testing market for cardiac diseases, 2020 - 2032
                           4.3.2.3 Hereditary genetic testing for rare disease
                               4.3.2.3.1 Global hereditary genetic testing market for rare diseases, 2020 - 2032
                           4.3.2.4 Hereditary genetic testing for other diseases
                               4.3.2.4.1 Global hereditary genetic testing market for other diseases, 2020 - 2032
                       4.3.3 Newborn genetic screening
                           4.3.3.1 Global newborn genetic screening market for inherited conditions, 2020 - 2032
                       4.3.4 Preimplantation Genetic Diagnosis & Screening (PGD/PGS)
                           4.3.4.1 Global PGD/PGS market for inherited conditions, 2020 - 2032
                       4.3.5 Non-invasive prenatal testing (NIPT) & carrier screening
                           4.3.5.1 Global non-invasive prenatal testing (NIPT) & carrier screening tests market for inherited conditions, 2020 - 2032
Chapter 5 Hereditary Testing Market: Technology Estimates & Trend Analysis
                   5.1 Hereditary Testing Market: Technology Movement Analysis
                   5.2 Cytogenetic
                       5.2.1 Global cytogenetic hereditary testing market, 2020 - 2032
                   5.3 Biochemical
                       5.3.1 Global biochemical hereditary testing market, 2020 - 2032
                   5.4 Molecular Testing
                       5.4.1 Global molecular testing market, 2020 - 2032
Chapter 6 Hereditary Testing Market Categorization: Regional Estimates & Trend Analysis by Disease Type
                   6.1 Hereditary Testing Market Share By Region
                   6.2 North America
                       6.2.1 North America hereditary testing market, 2020 - 2032
                       6.2.2 U.S.
                           6.2.2.1 U.S. hereditary testing market, by disease type, 2020 - 2032
                           6.2.2.2 U.S. hereditary testing market, by technology, 2020 - 2032
                       6.2.3 Canada
                           6.2.3.1 Canada hereditary testing market, by disease type, 2020 - 2032
                           6.2.3.2 Canada hereditary testing market, by technology, 2020 - 2032
                   6.3 Europe
                       6.3.1 Europe hereditary testing market, by disease type, 2020 - 2032
                       6.3.2. Europe hereditary testing market, by technology, 2020 - 2032
                       6.3.3 U.K.
                           6.3.3.1. U.K. hereditary testing market, by disease type, 2020 - 2032
                           6.3.3.2 U.K. hereditary testing market, by technology, 2020 - 2032
                       6.3.4 Germany
                           6.3.4.1 Germany hereditary testing market, by disease type, 2020 - 2032
                           6.3.4.2 Germany hereditary testing market, by technology, 2020 - 2032
                       6.3.5 France
                           6.3.5.1 France hereditary testing market, by disease type, 2020 - 2032
                           6.3.5.2 France hereditary testing market, by technology, 2020 - 2032
                       6.3.6 Spain
                           6.3.6.1 Spain hereditary testing market, by disease type, 2020 - 2032
                           6.3.6.2 Spain hereditary testing market, by technology, 2020 - 2032
                       6.3.7 Italy
                           6.3.7.1 Italy hereditary testing market, by disease type, 2020 – 2032
                           6.3.7.2 Italy hereditary testing market, by technology, 2020 - 2032
                       6.3.8 Netherlands
                           6.3.8.1 Netherlands hereditary testing market, by disease type, 2020 - 2032
                           6.3.8.2 Netherlands hereditary testing market, by technology, 2020 - 2032
                   6.4 Asia Pacific
                       6.4.1 Asia Pacific hereditary testing market, by disease type, 2020 - 2032
                       6.4.2. Asia Pacific hereditary testing market, by technology, 2020 - 2032
                       6.4.3 China
                           6.4.3.1 China hereditary testing market, by disease type, 2020 - 2032
                           6.4.3.1 China hereditary testing market, by technology, 2020 - 2032
                       6.4.4 Japan
                           6.4.4.1 Japan hereditary testing market, by disease type, 2020 - 2032
                           6.4.4.2 Japan hereditary testing market, by technology, 2020 - 2032
                       6.4.5 India
                           6.4.5.1 India hereditary testing market, by disease type, 2020 - 2032
                           6.4.5.2 India hereditary testing market, by technology, 2020 - 2032
                       6.4.6 South Korea
                           6.4.6.1 South Korea hereditary testing market, by disease type, 2020 - 2032
                           6.4.6.2 South Korea hereditary testing market, by technology, 2020 - 2032
                       6.4.7 Australia
                           6.4.7.1 Australia hereditary testing market, by disease type, 2020 - 2032
                           6.4.7.2 Australia hereditary testing market, by technology, 2020 - 2032
                       6.4.8 Singapore
                           6.4.8.1 Singapore hereditary testing market, by disease type, 2020- 2032
                           6.4.8.2 Singapore hereditary testing market, by technology, 2020 - 2032
                       6.4.9 South East Asia
                           6.4.9.1 South East Asia hereditary testing market, by disease type, 2020 - 2032
                           6.4.9.2 South East Asia hereditary testing market, by technology, 2020 - 2032
                   6.5 Latin America
                       6.5.1 Latin America hereditary testing market, by disease type, 2020 - 2032
                       6.5.2. Latin America hereditary testing market, by technology, 2020 - 2032
                       6.5.2 Brazil
                           6.5.2.1 Brazil hereditary testing market, by disease type, 2020 - 2032
                           6.5.2.2 Brazil hereditary testing market, by technology, 2020 - 2032
                   6.6 Middle East and Africa (MEA)
                       6.6.1 MEA hereditary testing market, by disease type, 2020 - 2032
                       6.6.2 MEA hereditary testing market, by technology, 2020 - 2032
                       6.6.3 South Africa
                           6.6.2.1 South Africa hereditary testing market, by disease type, 2020 - 2032
                           6.6.2.2 South Africa hereditary testing market, by technology, 2020 - 2032
Chapter 7 Competitive Landscape
                   7.1 Major Deals & Strategic Alliances Analysis
                       7.1.1 Merger & acquisition deals
                       7.1.2 Product launches
                       7.1.3 Technological & marketing collaboration
                   7.2 Company Profiles
                       7.2.1 Myriad Genetics, Inc.
                           7.2.1.1 Company overview
                           7.2.1.2 Counsyl, Inc.
                               7.2.1.2.1 Company overview
                           7.2.1.3 Financial performance
                           7.2.1.4 Product benchmarking
                           7.2.1.5 Strategic initiatives
                       7.2.2 Invitae Corporation
                           7.2.2.1 Company overview
                           7.2.2.2 Financial performance
                           7.2.2.3 Product benchmarking
                           7.2.2.4 Strategic initiatives
                       7.2.3 Illumina, Inc.
                           7.2.3.1 Company overview
                           7.2.3.2 Financial performance
                           7.2.3.3 Product benchmarking
                           7.2.3.4 Strategic initiatives
                       7.2.4 Natera Inc.
                           7.2.4.1 Company overview
                           7.2.4.2 Financial performance (Novartis AG)
                           7.2.4.3 Product benchmarking
                           7.2.4.4 Strategic initiatives
                       7.2.5 Laboratory Corporation of America Holdings
                           7.2.5.1 Company overview
                               7.2.5.1.1 Sequenom
                           7.2.5.2 Financial performance
                           7.2.5.3 Financial performance
                           7.2.5.4 Product benchmarking
                           7.2.5.5 Strategic initiatives
                       7.2.6 F. Hoffmann-La Roche Ltd.
                           7.2.6.1 Company overview
                           7.2.6.2 Ariosa Diagnostics
                           7.2.6.3 Financial performance
                           7.2.6.4 Product benchmarking
                           7.2.6.5 Strategic initiatives
                       7.2.7 Quest Diagnostics Incorporated
                           7.2.7.1 Company overview
                           7.2.7.2 Financial Performance
                           7.2.7.3 Product Benchmarking
                           7.2.7.4 Strategic initiatives
                       7.2.8 CooperSurgical, Inc.
                           7.2.8.1 Company overview
                               7.2.8.1.1 Genesis Genetics
                               7.2.8.1.2 Reprogenetics
                           7.2.8.2 Financial performance
                           7.2.8.3 Financial performance
                           7.2.8.4 Product benchmarking
                           7.2.8.5 Strategic initiatives
                       7.2.9 Agilent Technologies, Inc.
                           7.2.9.1 Company overview
                           7.2.9.2 Financial performance
                           7.2.9.3 Product benchmarking
                           7.2.9.4 Strategic initiatives
                       7.2.10 Thermo Fisher Scientific, Inc.
                           7.2.10.1 Company overview
                               7.2.10.1.1 Life Technologies Corp.
                           7.2.10.2 Financial performance
                           7.2.10.3 Product benchmarking
                           7.2.10.4 Strategic initiatives
                       7.2.11 Twist Bioscience
                           7.2.11.1 Company overview
                           7.2.11.2 Financial performance
                           7.2.11.3 Product benchmarking
                           7.2.11.4 Strategic initiatives
                       7.2.12 Sophia Genetics
                           7.2.1.2.1 Company overview
                           7.2.1.2.2  Financial performance
                           7.2.1 2.3 Product benchmarking
                           7.2.1 2.4 Strategic initiatives
                       7.2.13 Fulgent Genetics, Inc.
                           7.2.13.1 Company overview
                           7.2.13.2 Financial performance
                           7.2.13.3 Product benchmarking
                           7.2.13.4 Strategic initiatives
                       7.2.14 MedGenome
                           7.2.14.1 Company overview
                           7.2.14.2  Financial performance
                           7.2.14.3 Product benchmarking
                       7.2.15 CENTOGENE N.V.
                           7.2.15.1 Company overview
                           7.2.15.2 Financial performance
                           7.2.15.3 Product benchmarking
                           7.2.15.4 Strategic initiatives

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask To Expert